{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:49:14Z","timestamp":1783572554979,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eisai Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5674-5","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T16:03:54Z","timestamp":1560441834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-3428","authenticated-orcid":false,"given":"Lee","family":"Schwartzberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Puhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Berrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"5674_CR1","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1634\/theoncologist.2011-0159","volume":"16","author":"W Irvin Jr","year":"2011","unstructured":"Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 2011;16:1203\u201314.","journal-title":"Oncologist."},{"issue":"2","key":"5674_CR2","first-page":"1","volume":"12","author":"C Twelves","year":"2014","unstructured":"Twelves C, Gradishar WJ, O\u2019Shaughnessy JA, Bramsen B, Lurie RH. Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer. Clin Adv Hematol Oncol. 2014;12(2 suppl 4):1\u201314.","journal-title":"Clin Adv Hematol Oncol"},{"key":"5674_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/S1478951506060068","volume":"4","author":"B Grabsch","year":"2006","unstructured":"Grabsch B, Clarke DM, Love A, McKenzie DP, Snyder RD, Bloch S, et al. Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey. Palliat Support Care. 2006;4:47\u201356.","journal-title":"Palliat Support Care"},{"key":"5674_CR4","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines)\u00ae: breast Cancer version 3.2014","author":"National Comprehensive Cancer Network","year":"2014","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines)\u00ae: breast Cancer version 3.2014. Fort Washington: National Comprehensive Cancer Network; 2014."},{"key":"5674_CR5","volume-title":"Halaven\u00ae (eribulin mesylate) injection [prescribing information]","author":"Eisai Inc","year":"2014","unstructured":"Eisai Inc. Halaven\u00ae (eribulin mesylate) injection [prescribing information]. Woodcliff Lake: Eisai Inc; 2014."},{"key":"5674_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323.","journal-title":"Lancet."},{"issue":"6","key":"5674_CR7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracyclines and a taxane. J Clin Oncol. 2015;33(6):594\u2013601.","journal-title":"J Clin Oncol"},{"key":"5674_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"5674_CR9","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te VA, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756\u201368.","journal-title":"J Clin Oncol"},{"key":"5674_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"5674_CR11","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265\u201374.","journal-title":"J Clin Oncol"},{"key":"5674_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3816\/CBC.2010.n.037","volume":"10","author":"H Rugo","year":"2010","unstructured":"Rugo H, Brammer M, Zhang F, Lalla D. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer. 2010;10:288\u201393.","journal-title":"Clin Breast Cancer"},{"key":"5674_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-014-2923-9","volume":"146","author":"K McIntyre","year":"2014","unstructured":"McIntyre K, O'Shaughnessy J, Schwartzberg L, Gluck S, Berrak E, Song JX, et al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat. 2014;146:321\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"5674_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clbc.2014.04.004","volume":"14","author":"S Wilks","year":"2014","unstructured":"Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer. 2014;14:405\u201312.","journal-title":"Clin Breast Cancer."},{"key":"5674_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139\u201344.","journal-title":"J Clin Oncol"},{"key":"5674_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30. J Clin Oncol. 2011;29:89\u201396.","journal-title":"J Clin Oncol"},{"key":"5674_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ejca.2004.01.014","volume":"40","author":"F Efficace","year":"2004","unstructured":"Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004;40:1021\u201330.","journal-title":"Eur J Cancer"},{"key":"5674_CR18","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0959-8049(00)00144-1","volume":"36","author":"JA Kramer","year":"2000","unstructured":"Kramer JA, Curran D, Piccart M, de Haes JCJM, Bruning P, Klijn J, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer. 2000;36:1498\u2013506.","journal-title":"Eur J Cancer"},{"key":"5674_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cncr.28382","volume":"120","author":"C Quinten","year":"2014","unstructured":"Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120:302\u201311.","journal-title":"Cancer."},{"key":"5674_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12032-011-9844-9","volume":"29","author":"H Svensson","year":"2012","unstructured":"Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol. 2012;29:432\u20138.","journal-title":"Med Oncol"},{"key":"5674_CR21","doi-asserted-by":"crossref","unstructured":"Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005:CD003372.","DOI":"10.1002\/14651858.CD003372.pub2"},{"key":"5674_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/annonc\/mdf306","volume":"13","author":"E Heidemann","year":"2002","unstructured":"Heidemann E, Stoeger H, Souchon R, Hirschmann WD, Bodenstein H, Oberhoff C, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol. 2002;13:1717\u201329.","journal-title":"Ann Oncol"},{"key":"5674_CR23","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1200\/JCO.1998.16.12.3720","volume":"16","author":"H Joensuu","year":"1998","unstructured":"Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998;16:3720\u201330.","journal-title":"J Clin Oncol"},{"key":"5674_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-642-72983-6_7","volume-title":"Endocrine therapy of breast cancer II: current developments and new methodologies","author":"KW Brunner","year":"1987","unstructured":"Brunner KW. Evaluation criteria in comparative clinical trials in advanced breast cancer: a proposal for improvement. In: Cavalli F, editor. Endocrine therapy of breast cancer II: current developments and new methodologies. Berlin: Springer-Verlag; 1987. p. 47\u201351."},{"key":"5674_CR25","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.1990.434","volume":"62","author":"JCJM de Haes","year":"1990","unstructured":"de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam symptom checklist. Br J Cancer. 1990;62:1034\u20138.","journal-title":"Br J Cancer"},{"key":"5674_CR26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","volume":"17","author":"JM Nabholtz","year":"1999","unstructured":"Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group. J Clin Oncol. 1999;17:1413\u201324.","journal-title":"J Clin Oncol"},{"key":"5674_CR27","first-page":"73","volume":"13","author":"RJ Simes","year":"1994","unstructured":"Simes RJ, Gebski VJ, Coates AS, Forbes J, Harvey V, Van Hazel G, et al. Quality of life (QOL) with single agent mitozantrone (MTZ) or combination chemotherapy (CMFP) for advanced breast cancer: a randomised trial [abstract]. Proc Am Soc Clin Oncol. 1994;13:73.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5674_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","volume":"34","author":"WO Spitzer","year":"1981","unstructured":"Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34:585\u201397.","journal-title":"J Chronic Dis"},{"issue":"12","key":"5674_CR29","doi-asserted-by":"publisher","first-page":"CD008792","DOI":"10.1002\/14651858.CD008792.pub2","volume":"18","author":"RF Dear","year":"2013","unstructured":"Dear RF, Mc Geechan K, Jenkins MC, Barratt A, Tattersall MHN, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2013;18(12):CD008792. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008792.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"key":"5674_CR30","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1200\/JCO.2002.03.090","volume":"20","author":"D Osoba","year":"2002","unstructured":"Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20:3106\u201313.","journal-title":"J Clin Oncol"},{"key":"5674_CR31","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","volume":"24","author":"J Cortes","year":"2013","unstructured":"Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013;24:2630\u20135.","journal-title":"Ann Oncol"},{"key":"5674_CR32","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1200\/JCO.2012.44.7912","volume":"31","author":"L Gianni","year":"2013","unstructured":"Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer. J Clin Oncol. 2013;31:1719\u201325.","journal-title":"J Clin Oncol"},{"key":"5674_CR33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","volume":"31","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157\u201363.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5674-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5674-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5674-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T23:18:59Z","timestamp":1591917539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5674-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5674"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5674-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both studies were conducted in accordance with the Declaration of Helsinki (2008), and the protocol and informed consent forms were submitted for approval to institutional review boards. All patients provided written informed consent prior to any study-related procedures. A complete list of participating trial sites and institutional review boards is provided as an additional file.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LS is a consultant\/adviser for and has received funding from Eisai Inc., and Helsinn.KM has no conflict of interest to disclose.SW has no conflict of interest to disclose.SP is a consultant for Celldex, MedImmune, Pfizer, AbbVie, AstraZeneca, Eisai, and Puma.JO is a consultant\/adviser for Eisai Inc.EB and YH are former employees of Eisai Inc.LV is a consultant\/adviser for Eisai Inc., Bristol-Myers Squibb Oncology, and Berg Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"578"}}